Elsa Arbajian

Dr. Elsa Arbajian

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
EAElsa Arbajian
Elsa Arbajian
FPFlorian Puls
Florian Puls
LMLinda Magnusson
Linda Magnusson
KTKhin Thway
Khin Thway
CFCyril Fisher
Cyril Fisher
FMFredrik Mertens
Fredrik Mertens
Sclerosing epithelioid fibrosarcoma (SEF) and low-grade fibromyxoid sarcoma (LGFMS) are 2 distinct types of sarcoma, with a subset of cases showing overlapping morphologic and immunohistochemical features. LGFMS is characterized by expression of the MUC4 protein, and about 90% of cases display a distinctive FUS-CREB3L2 gene fusion. In addition, SEF is often MUC4 positive, but is genetically less well studied. Fluorescence in situ hybridization (FISH) studies have shown involvement of the FUS gene in the majority of so-called hybrid LGFMS/SEF and in 10% to 25% of sarcomas with pure SEF morphology. In this study, we investigated a series of 10 primary tumors showing pure SEF morphology, 4 cases of LGFMS that at local or distant relapse showed predominant SEF morphology, and 1 primary hybrid LGFMS/SEF. All but 1 case showed diffuse expression for MUC4. Using FISH, reverse transcription polymerase chain reaction, and/or mRNA sequencing in selected cases, we found recurrent EWSR1-CREB3L1 fusion transcripts by reverse transcription polymerase chain reaction in 3/10 pure SEF cases and splits and deletions of the EWSR1 and/or CREB3L1 genes by FISH in 6 additional cases. All 5 cases of LGFMS with progression to SEF morphology or hybrid features had FUS-CREB3L2 fusion transcripts. Our results indicate that EWSR1 and CREB3L1 rearrangements are predominant over FUS and CREB3L2 rearrangements in pure SEF, highlighting that SEF and LGFMS are different tumor types, with different impacts on patient outcome.

30 November 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EAElsa Arbajian
Elsa Arbajian
FPFlorian Puls
Florian Puls
CACristina R. Antonescu
Cristina R. Antonescu
FAFernanda Amary
Fernanda Amary
RSRaf Sciot
Raf Sciot
FMFredrik Mertens
Fredrik Mertens
Purpose: Sclerosing epithelioid fibrosarcoma (SEF) is a highly aggressive soft tissue sarcoma closely related to low-grade fibromyxoid sarcoma (LGFMS). Some tumors display morphologic characteristics of both SEF and LGFMS, hence they are known as hybrid SEF/LGFMS. Despite the overlap of gene fusion variants between these two tumor types, SEF is much more aggressive. The current study aimed to further characterize SEF and hybrid SEF/LGFMS genetically to better understand the role of the characteristic fusion genes and possible additional genetic alterations in tumorigenesis. Experimental Design: We performed whole-exome sequencing, SNP array analysis, RNA sequencing (RNA-seq), global gene expression analyses, and/or IHC on a series of 13 SEFs and 6 hybrid SEF/LGFMS. We also expressed the FUS-CREB3L2 and EWSR1-CREB3L1 fusion genes conditionally in a fibroblast cell line; these cells were subsequently analyzed by RNA-seq, and expression of the CD24 protein was assessed by FACS analysis. Results: The SNP array analysis detected a large number of structural aberrations in SEF and SEF/LGFMS, many of which were recurrent, notably DMD microdeletions. RNA-seq identified FUS-CREM and PAX5-CREB3L1 as alternative fusion genes in one SEF each. CD24 was strongly upregulated, presumably a direct target of the fusion proteins. This was further confirmed by the gene expression analysis and FACS analysis on Tet-On 3G cells expressing EWSR1-CREB3L1. Conclusions: Although gene fusions are the primary tumorigenic events in both SEF and LGFMS, additional genomic changes explain the differences in aggressiveness and clinical outcome between the two types. CD24 and DMD constitute potential therapeutic targets. Clin Cancer Res; 23(23); 7426–34. ©2017 AACR.

1 January 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
EAElsa Arbajian
Elsa Arbajian
JKJan Köster
Jan Köster
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
FMFredrik Mertens
Fredrik Mertens

10 December 2012 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
EAElsa Arbajian
Elsa Arbajian
LMLinda Magnusson
Linda Magnusson
FMFredrik Mertens
Fredrik Mertens
HDHenryk A. Domanski
Henryk A. Domanski
FSFredrik Vult von Steyern
Fredrik Vult von Steyern
KNKarolin H. Nord
Karolin H. Nord

1 March 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
AFAndrew L. Folpe
Andrew L. Folpe
APAntonio R. Perez-Atayde
Antonio R. Perez-Atayde
KPKyle Perry
Kyle Perry
JHJakob Hofvander
Jakob Hofvander
FMFredrik Mertens
Fredrik Mertens

22 June 2017 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
EBElise M Bekers
Elise M Bekers
PGPatricia Jta Groenen
Patricia Jta Groenen
MVMarian Aj Verdijk
Marian Aj Verdijk
WGWinny L Raaijmakers‐Van Geloof
Winny L Raaijmakers‐Van Geloof
PRPaul Roepman
Paul Roepman
UFUta E. Flucke
Uta E. Flucke